Radiotargeting agents for cancer therapy

Bibliography

• WALICKA MA, VAIDYANATHAN G, ZALUTSKY MR, ADELSTEIN SJ, KASSIS AT: Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat. Res. (1998) 150:263–268.
   Google Scholar
• •Experimental demonstration of the effects of nonuniform irradiation by a-particles on cell survival.
   Google Scholar
• GODDU SM, HOWELL RW, RAO DV: Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. Nucl. Med. (1994) 35:303–316.
   Google Scholar
• ••The tables within are essential for dosecalculations at the cellular level.
   Google Scholar
• SASTRY KSR, HOWELL RW, RAO DVet al.: Dosimetry of Auger emitters: physical and phenomenological approaches. In: DNA Damage by Auger Emitters. KF B DE Charlton (Eds.), Taylor and Francis, London, UK (1988):27–38.
   Google Scholar
• WRIGHT HA, HAMM RN, TURNER JE, HOWELL RW, RAO DV, SASTRY KS: Calculations of physical and chemical reactions with DNA in aqueous solution from Auger cascades. Radiat. Prot. Doslin. (1990) 31:59–62.
   Google Scholar
• KASSIS AT, ADELSTEIN SJ, HAYDOCK C, SASTRY KS: Radiotoxicity of 755e and 35S: theory and application to a cellular model. Radiat. Res. (1980) 84:407–425.
   Google Scholar
• •• Methods for subcellular dosimetry.
   Google Scholar
• KASSIS Al, ADELSTEIN SJ, HAYDOCK C, SASTRY KS, MCELVANY KD, WELCH MJ: Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat. Res. (1982) 90:362–373.
   Google Scholar
• KASSIS Al, SASTRY KS, ADELSTEIN SJ: Intracellular localisation of Auger electron emitters: biophysical dosimetry. Radiat. Prot. Dosim. (1985) 13:233–236.
   Google Scholar
• XUE LY, BUTLER NJ, MAKRIGIORGOS GM, ADELSTEIN SJ, KASSIS Al: Bystander effect produced by radiolabeled tumor cells in vivo. Proc. Natl. Acad. Sci. USA (2002) 99:13765–13770.
   Google Scholar
• ••The first demonstration of Auger-electron-induced bystander effect in animals.
   Google Scholar
• HUMM JL, CHIN LM, COBB L, BEGENT R: Microdosimetry in radioimmunotherapy. Radiat. Prot. Dosim. (1990) 31:433–436.
   Google Scholar
• ICRU Report 67). ICRU(2002) 2(1):1–110.
   Google Scholar
• •Source for absorbed doses.
   Google Scholar
• DONOGHUE JA: The impact of tumorcell proliferation in radioimmunotherapy. Cancer (1994) 73:974–980.
   Google Scholar
• JAIN RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. (1990) 50 (Suppl. 3):814s–819s.
   Google Scholar
• •An excellent overview addressing the factors underlying the barriers opposing the diffusion of molecules throughout tumours.
   Google Scholar
• NETTI PA, HAMBERG LM, BABICH JW et al.: Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA (1999) 96:3137–3142.
   Google Scholar
• •Concepts relating to the diffusion of macromolecules throughout tumours.
   Google Scholar
• KASSIS Al, HARRIS CR, ADELSTEIN SJ, RUTH TJ, LAMBRECHT R, WOLF AP: The in vitro radiobiology of astatine-211 decay. Radiat. Res. (1986) 105:27–36.
   Google Scholar
• CHARLTON DE, KASSIS Al, ADELSTEIN SJ: A comparison of experimental and calculated survival curves for V79 cells grown as monolayers or in suspension exposed to alpha irradiation from 212Bi distributed in the growth medium. Radiat. Prot. Dosim. (1994) 52:311–315.
   Google Scholar
• BLOOMER WD, MCLAUGHLIN WH, LAMBRECHT RM et al: 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 60Y. Lit. I Radiat. Oncol Biol. Phys. (1984) 10:341–348.
   Google Scholar
• ••An excellent demonstration of thetherapeutic potential of a-particles in vivo.
   Google Scholar
• MACKLIS RIVI, KINSEY BM, KASSIS Al et al: Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science (1988) 240:1024–1026.
   Google Scholar
• ZALUTSKY MR, MCLENDON RE, GARG PK, ARCHER GE, SCHUSTER JM, BIGNER DD: Radioimmunotherapy of neoplastic meningitis in rats using an a-particle-emitting immunoconjugate. Cancer Res. (1994) 54:4719–4725.
   Google Scholar
• MCDEVITT MR, LAI LT et al.: Tumor therapy with targeted atomic nanogenerators. Science (2001) 294:1537–1540.
   Google Scholar
• CHAN PC, LISCO E, LISCO H, ADELSTEIN SJ: The radiotoxicity of iodine-125 in mammalian cells. II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131IUdR, and 31-1TdR. Radiat. Res. (1976) 67:332–343.
   Google Scholar
• BURKI HJ, KOCH C, WOLFF S: Molecular suicide studies of 1251 and 314 disintegration in the DNA of Chinese hamster cells. Curr. Top. Radiat. Res. Q. (1977) 12:408–425.
   Google Scholar
• ESTEBAN JM, SCHLOM J, MORNEX F,COLCHER D: Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur. .1 Cancer Clin. Oncol (1987) 23:643–655.
   Google Scholar
• OTTE A, MUELLER-BRAND J, DELLAS S, NITZSCHE EU, HERRMANN R, MAECKE HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (1998) 351:417–418.
   Google Scholar
• CHINN PC, LEONARD JE, ROSENBERG J, HANNA N, ANDERSON DR: Preclinical evaluation of 60Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Lit. Oncol (1999) 15:1017–1025.
   Google Scholar
• AXWORTHY DB, RENO JM, HYLARIDES MD et al: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA (2000) 97:1802–1807.
   Google Scholar
• ••An excellent demonstration of thetherapeutic potential of 0-particles in vivo.
   Google Scholar
• DENARDO GL, KUKIS DL, SHEN S et al: Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin. Cancer Res. (1997) 3:71–79.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al: Radioimmunotherapy of B-cell lymphoma with [1311]anti-B1 (anti-CD20) antibody. N Engl. I Med. (1993) 329:459–465.
   Google Scholar
• WITZIG TE: Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (2004) 40:111–119.
   Google Scholar
• KAMINSKI MS, TUCK M, ESTES Jet al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N EngL J. Med. (2005) 352:441–449.
   Google Scholar
• KASSIS Al, ADELSTEIN SJ, HAYDOCK C, SASTRY KS: Thallium-201: an experimental and a theoretical radiobiological approach to dosimetry. J. Nucl. Med. (1983) 24:1164–1175.
   Google Scholar
• KASSIS Al, SASTRY KS, ADELSTEIN SJ: Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry. J. Nucl. Med. (1985) 26:59–67.
   Google Scholar
• KASSIS Al, SASTRY KS, ADELSTEIN SJ: of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radial-. Res. (1987) 109:78–89.
   Google Scholar
• •Dosimetry of DNA-incorporated Auger-electron emitters.
   Google Scholar
• KASSIS Al, FAYAD F, KINSEY BM, SASTRY KS, TAUBE RA, ADELSTEIN SJ: Radiotoxicity of 1251 in mammalian cells. Radial-. Res. (1987) 111:305–318.
   Google Scholar
• KASSIS Al, MAKRIGIORGOS GM, ADELSTEIN SJ: Implications of radiobiological and dosimetric studies of DNA-incorporated 1231: the use of the Auger effect as a biological probe at the nanometre level. Radiat. Prot. Dosim. (1990) 31:333–338.
   Google Scholar
• •The biophysical aspects of low energy electron irradiation.
   Google Scholar
• HOFER KG, HUGHES WL: Radiotoxicity intranuclear tritium, 125iodine and 131iodine. Radiat. Res. (1971) 47:94–109.
   Google Scholar
• BLOOMER WD, MCLAUGHLIN WH, WEICHSELBAUM RR et al: Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. Int. Radiat. Biol. (1980) 38:197–202.
   Google Scholar
• WALICKA MA, ROY AM, HARAPANHALLI RS, ADELSTEIN SJ, KASSIS AT: Cytotoxicity of [125I]iodoHoechst 33342: contribution of scavengeable effects. bit. .1 Radiat. Biol. (1999) 75:1579–1587.
   Google Scholar
• HOFER KG, HARRIS CR, SMITH JM:Radiotoxicity of intracellular 67Ga, 1251 and 3H: nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. hit. J. Radiat. Biol. (1975) 28:225–241.
   Google Scholar
• •The first demonstration of the marked differences in the radiotoxicity of Auger-electron irradiation when the radionuclide is localised within the cytoplasm or the nuclei of mammalian cells.
   Google Scholar
• BLOOMER WD, ADELSTEIN SJ: 5-1251-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature (1977) 265:620–621.
   Google Scholar
• ••The first demonstration of the therapeuticefficacy of Auger electrons in vivo.
   Google Scholar
• BARANOWSKA-KORTYLEWICZ J, MAKRIGIORGOS GM, VAN ABBEELE AD, BERMAN RM, ADELSTEIN SJ, KASSIS Al: 54123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int. j Radiat. Oncol Biol. Phys. (1991) 21:1541–1551.
   Google Scholar
• KASSIS Al, DAHMAN BA, ADELSTEIN SJ: LI vivo therapy of neoplastic meningitis with methotrexate and 5- [125I] iodo- 2 '-de oxyuridine. Acta Oncol (2000) 39:731–737.
   Google Scholar
• KASSIS Al, KIRICHIAN AM, WANG K, SEMNANI E, ADELSTEIN SJ: Therapeutic potential of 5- [125I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int. J. Radiat. Biol. (2004) 80:941–946.
   Google Scholar
• ••An excellent demonstration of thetherapeutic potential of Auger electrons in solid tumours.
   Google Scholar